Want to see GCTK full AI Analyst Report?
GCTK Stock Chart & Stats
$0.29
$0.01(4.36%)
At close: 4:00 PM EDT
$0.29
$0.01(4.36%)
Day’s Range― - ―
52-Week Range$0.25 - $14.14
Previous Close$0.3
Volume246.34K
Average Volume (3M)2.54M
Market Cap
$3.68M
Enterprise Value$2.43
Total Cash (Recent Filing)$1.12M
Total Debt (Recent Filing)$19.00K
Price to Earnings (P/E)―
Beta2.31
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.03
Shares Outstanding10,578,822
10 Day Avg. Volume100,775
30 Day Avg. Volume2,541,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.23
Price to Sales (P/S)0.00
P/FCF Ratio-0.23
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Debt BurdenMinimal debt limits near-term interest and repayment pressure, giving the company more flexibility to direct available capital toward clinical development and operations despite its weak equity position.
New Growth FinancingThe financing provides capital to continue diabetes technology and biopharmaceutical development, extending operational capacity and reducing immediate dependence on smaller, repeated funding transactions.
Simplified LT-100 AdministrationA single-injection regimen could reduce patient treatment burden and simplify trial logistics, potentially improving the product’s clinical usability and commercial positioning if later studies confirm the approach.
Bears Say
No Demonstrated RevenueA lack of revenue indicates that GlucoTrack has not yet demonstrated commercialization traction. Continued dependence on development milestones leaves future funding and business viability reliant on unproven product adoption.
Accelerating Cash BurnPersistently negative and worsening operating cash flow shows that core activities consume substantial capital. This increases reliance on external financing and raises the risk that development will be interrupted.
Equity Instability And DilutionNegative equity reflects accumulated losses and weak financial resilience, while equity-linked funding can dilute existing holders. Together, these factors may constrain financing options and reduce shareholder participation in future upside.
GlucoTrack News
GCTK FAQ
What was GlucoTrack’s price range in the past 12 months?
GlucoTrack lowest stock price was $0.25 and its highest was $14.14 in the past 12 months.
What is GlucoTrack’s market cap?
GlucoTrack’s market cap is $3.68M.
When is GlucoTrack’s upcoming earnings report date?
GlucoTrack’s upcoming earnings report date is Nov 12, 2026 which is in 80 days.
How were GlucoTrack’s earnings last quarter?
GlucoTrack released its earnings results on Aug 13, 2026. The company reported -$0.761 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is GlucoTrack overvalued?
According to Wall Street analysts GlucoTrack’s price is currently Overvalued.
Does GlucoTrack pay dividends?
GlucoTrack does not currently pay dividends.
What is GlucoTrack’s EPS estimate?
GlucoTrack’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GlucoTrack have?
GlucoTrack has 10,578,822 shares outstanding.
What happened to GlucoTrack’s price movement after its last earnings report?
GlucoTrack reported an EPS of -$0.761 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.926%.
Which hedge fund is a major shareholder of GlucoTrack?
Currently, no hedge funds are holding shares in GCTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GlucoTrack
Based in Or Yehuda, Israel, GlucoTrack, Inc. is a medical technology company focused on innovating, developing, and bringing to market non-invasive glucose monitoring systems. Their primary offering, the GlucoTrack device, enables individuals with diabetes or pre-diabetes to painlessly check their blood glucose levels. This technology is available to customers both in Israel and across the globe. The company, founded in 2001, operated under the name Integrity Applications, Inc. until it officially rebranded to GlucoTrack, Inc. in November 2021.
Technical Analysis
Ownership Overview
0.11% Insiders
0.10% Mutual Funds
0.63% Other Institutional Investors
99.16% Public Companies and
Individual Investors